Pharmacokinetics (PK) and pharmacodynamics (PD) of SCIO-469, a p38 gamma MAP kinase inhibitor

D Amakye

Open source

DOI
10.1016/j.clpt.2003.11.203
Published
2004-02
Container
Clinical Pharmacology & Therapeutics
Publisher
Wiley
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.clpt.2003.11.203,
  title = {Pharmacokinetics (PK) and pharmacodynamics (PD) of SCIO-469, a p38 gamma MAP kinase inhibitor},
  author = {D Amakye},
  year = {2004},
  journal = {Clinical Pharmacology \& Therapeutics},
  doi = {10.1016/j.clpt.2003.11.203},
  url = {https://doi.org/10.1016/j.clpt.2003.11.203}
}

RIS

TY  - JOUR
TI  - Pharmacokinetics (PK) and pharmacodynamics (PD) of SCIO-469, a p38 gamma MAP kinase inhibitor
AU  - D Amakye
PY  - 2004
JO  - Clinical Pharmacology & Therapeutics
DO  - 10.1016/j.clpt.2003.11.203
UR  - https://doi.org/10.1016/j.clpt.2003.11.203
ER  - 

APA

Amakye, D. (2004). Pharmacokinetics (PK) and pharmacodynamics (PD) of SCIO-469, a p38 gamma MAP kinase inhibitor. Clinical Pharmacology & Therapeutics. https://doi.org/10.1016/j.clpt.2003.11.203

Source records